Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEAD1 | P28347 | 6/20 | 0.44 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.44 |
| ▸ | BTK | Q06187 | 7/20 | 0.40 |
| ▸ | JAK3 | P52333 | 4/20 | 0.38 |
| ▸ | JAK2 | O60674 | 2/20 | 0.36 |
| ▸ | JAK1 | P23458 | 2/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.36 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.36 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.36 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4739306 | 0.89 | JAK3 (0.45) | BTKJAK3JAK2JAK1 | |
| SCHEMBL4578429 | 0.89 | TEAD1 (0.50) | TEAD1TEAD3BTKJAK3JAK2 | |
| SCHEMBL16846933 | 0.84 | TEAD1 (0.43) | TEAD1TEAD3BTKJAK3FGFR1 | |
| SCHEMBL11950456 | 0.84 | TEAD1 (0.43) | TEAD1TEAD3BTKJAK3FGFR1 | |
| SCHEMBL19240545 | 0.84 | TEAD1 (0.43) | TEAD1TEAD3BTKJAK3FGFR1 | |
| SCHEMBL24492204 | 0.81 | TEAD1 (0.45) | TEAD1TEAD3BTKJAK3FGFR1 | |
| SCHEMBL16285098 | 0.81 | TEAD1 (0.42) | TEAD1TEAD3BTKJAK3JAK2 | |
| SCHEMBL16285115 | 0.81 | TEAD1 (0.45) | TEAD1TEAD3BTKJAK3FGFR1 | |
| SCHEMBL20892891 | 0.81 | TEAD1 (0.45) | TEAD1TEAD3BTKJAK3JAK2 | |
| SCHEMBL15474338 | 0.81 | THRA (0.47) | TEAD1TEAD3BTKJAK3FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023133543-A1 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2023-07-13 | — | — | WO | disclosed |
| WO-2021133894-A1 | BTK INHIBITORS | BIOGEN MA INC. (US) | 2021-07-01 | — | — | WO | disclosed |
| EP-3138842-B1 | POLYFLUORINATED COMPOUNDS ACTING AS BRUTON'S TYROSINE KINASE INHIBITORS | ZHEJIANG DTRM BIOPHARMA CO LTD (CN) | 2020-12-09 | — | — | EP | disclosed |
| US-10300066-B2 | Polyfluorinated compounds acting as bruton tyrosine kinase inhibitors | Zhejiang DTRM Biopharma Co. Ltd. (CN) | 2019-05-28 | — | — | US | disclosed |
| US-20180207161-A1 | POLYFLUORINATED COMPOUNDS ACTING AS BRUTON TYROSINE KINASE INHIBITORS | Zhejiang DTRM Biopharma Co. Ltd. (CN) | 2018-07-26 | — | — | US | disclosed |
| US-20170065594-A1 | POLYFLUORINATED COMPOUNDS ACTING AS BRUTON TYROSINE KINASE INHIBITORS | Zhejiang DTRM Biopharma Co. Ltd. (CN) | 2017-03-09 | — | — | US | disclosed |
| EP-3138842-A1 | POLYFLUORINATED COMPOUNDS ACTING AS BRUTON'S TYROSINE KINASE INHIBITORS | Zhejiang DTRM Biopharma Co., Ltd. (CN) | 2017-03-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170065594-A1 | POLYFLUORINATED COMPOUNDS ACTING AS BRUTON TYROSINE KINASE INHIBITORS | BTK, LCK, LYN | TEAD1 2701/4885TEAD3 2536/4885BTK 1/4885 |
| US-20180207161-A1 | POLYFLUORINATED COMPOUNDS ACTING AS BRUTON TYROSINE KINASE INHIBITORS | BTK, LCK, LYN | TEAD1 2701/4885TEAD3 2536/4885BTK 1/4885 |
| US-10300066-B2 | Polyfluorinated compounds acting as bruton tyrosine kinase inhibitors | BTK, LCK, LYN | TEAD1 2701/4885TEAD3 2536/4885BTK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.